Reduced intensity hematopoietic cell transplant using best available donor and posttransplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia

Over 300,000 live births annually are affected by hemoglobinopathies worldwide. Of these, transfusion-dependent thalassemias (TDTs) result in severe phenotypes that significantly impact quality of life, shorten life expectancy, and incur high lifetime healthcare costs driven by recurrent transfusions and chelation therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) is curative but limited by donor availability, regimen toxicity, graft-versus-host disease (GVHD), and transplant-related mortality. We present our single-center experience of TDT patients who underwent allo-HCT using a reduced-intensity conditioning (RIC) regimen (anti-thymocyte globulin, fludarabine, cyclophosphamide, total body irradiation) and posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Twenty-five consecutive children and young adults (ages 2-23 years, median 9) with TDT (beta-thalassemia major n=21, hemoglobin E-beta thalassemia n=3, hemoglobin D-beta thalassemia n=1) underwent HCT from July 2013 to November 2024. Bone marrow was the most common graft source (n=23, 92% of all patients), and haploidentical donors were the most common donor type (n=19, 76% of all patients). Neutrophil and platelet recovery occurred at median 21 days (range 13-38) and 26 days (range 16-88), respectively. Five patients (20%) developed grade I-II acute GVHD; none developed grade III-IV acute GVHD. Two (8%) developed mild chronic GVHD. At a median follow-up of 5.6 years (range 0.7-10), 5-year overall survival was 100%, transfusion-free survival 96%, and thalassemia-free-GVHD-free survival 96% - one patient experienced near-complete loss of donor chimerism with return of the TDT phenotype. Our RIC platform with best-available donor and PTCy-based GVHD prophylaxis significantly reduces post-HCT complications while providing durable transfusion independence, offering a proven, accessible, curative option for TDT.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-11-19
DOI
https://doi.org/10.3324/haematol.2026.301748
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reduced intensity hematopoietic cell transplant using best available donor and posttransplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia

Elias T. Zambidis, Javier Bolaños‐Meade, Heather Jill Symons, Kathryn Duke et al.
Haematologica
Hematopoietic Stem Cell Transplantation
article

Reduced intensity hematopoietic cell transplant using best available donor and posttransplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia

Elias T. Zambidis, Javier Bolaños‐Meade, Heather Jill Symons, Kathryn Duke, Lisa Vindiola, Rebecca S. Berger, Christopher J. Gamper, Kenneth R. Cooke, Nicolas Jose Llosa, Hua‐Ling Tsai, Challice Lee Bonifant, Megan Burris, Yiouli Panayiota Ktena, Richard Julian Jones, Jessica D Murphy, Katherine Liddle, Kristen Rodenbush, Sara Newton, Liam M. Cooke, Allen R. Chen
article en

Abstract

Over 300,000 live births annually are affected by hemoglobinopathies worldwide. Of these, transfusion-dependent thalassemias (TDTs) result in severe phenotypes that significantly impact quality of life, shorten life expectancy, and incur high lifetime healthcare costs driven by recurrent transfusions and chelation therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) is curative but limited by donor availability, regimen toxicity, graft-versus-host disease (GVHD), and transplant-related mortality. We present our single-center experience of TDT patients who underwent allo-HCT using a reduced-intensity conditioning (RIC) regimen (anti-thymocyte globulin, fludarabine, cyclophosphamide, total body irradiation) and posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Twenty-five consecutive children and young adults (ages 2-23 years, median 9) with TDT (beta-thalassemia major n=21, hemoglobin E-beta thalassemia n=3, hemoglobin D-beta thalassemia n=1) underwent HCT from July 2013 to November 2024. Bone marrow was the most common graft source (n=23, 92% of all patients), and haploidentical donors were the most common donor type (n=19, 76% of all patients). Neutrophil and platelet recovery occurred at median 21 days (range 13-38) and 26 days (range 16-88), respectively. Five patients (20%) developed grade I-II acute GVHD; none developed grade III-IV acute GVHD. Two (8%) developed mild chronic GVHD. At a median follow-up of 5.6 years (range 0.7-10), 5-year overall survival was 100%, transfusion-free survival 96%, and thalassemia-free-GVHD-free survival 96% - one patient experienced near-complete loss of donor chimerism with return of the TDT phenotype. Our RIC platform with best-available donor and PTCy-based GVHD prophylaxis significantly reduces post-HCT complications while providing durable transfusion independence, offering a proven, accessible, curative option for TDT.

Haematologica
Johns Hopkins University (US), Johns Hopkins Hospital (US), Sidney Kimmel Comprehensive Cancer Center (US)
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon